Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 53 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt’s scientific excellence, multidisciplinary research, and robust training and education. Moffitt’s expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. With more than 7,800 team members, Moffitt has an economic impact in the state of $2.4 billion. For more information, call 1-888-MOFFITT (1-888-663-3488), visit MOFFITT.org, and follow the momentum on Facebook, Twitter, Instagram and YouTube.
March 13, 2024
Video
Bruna Pellini, MD, discusses the utility of circulating tumor DNA assays in non–small cell lung cancer.
March 13, 2024
Video
Ariel F. Grajales-Cruz, MD, discusses the real-world efficacy of teclistamab in relapsed/refractory multiple myeloma.
March 07, 2024
Video
Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.
March 07, 2024
Video
Medical experts provide key takeaways and impacts from the FRESCO-2 study.
March 01, 2024
Video
The expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.
February 29, 2024
Video
Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.
February 29, 2024
Video
Key safety considerations for the use of fruquintinib are explored.
February 28, 2024
Video
Jobelle Baldonado, MD, discusses the evolution of personalized approaches to treatment in non–small cell lung cancer.
February 28, 2024
Article
The National Comprehensive Cancer Network recommends ropeginterferon alfa-2b as first-line cytoreductive therapy for polycythemia vera.
February 27, 2024
Video
Ariel Grajales-Cruz, MD, discusses factors associated with benefit from teclistamab in heavily pretreated relapsed/refractory multiple myeloma.
February 23, 2024
Video
Speculation on anticipated innovations in allo-HSCT and cellular therapy technologies in the future.
February 23, 2024
Video
The expert panel shares emerging data on an engineered, allogeneic cell-based therapy administered as part of conditioning for allo-HSCT in patients with relapsed, refractory, or high-risk hematologic cancers.
February 22, 2024
Video
Dae Won Kim, MD, discusses findings from the NAPOLI 3 trial that support the use of NALIRIFOX in patients with metastatic pancreatic cancer.
February 22, 2024
Video
Dr Parikh drives a conversation surrounding 3L treatment for patients diagnosed with metastatic colorectal cancer.
February 22, 2024
Video
Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.
February 21, 2024
Article
David A. Sallman, MD, discusses the potential use of fedratinib to manage symptomatic myelodysplastic syndrome/myeloproliferative neoplasms.
February 20, 2024
Video
John M. Bryant, MD, discusses how identifying germline DNA repair mutations may impact the development of targeted therapy development in PDAC.
February 20, 2024
Video
A panel of experts discuss future directions and remaining unmet needs for patients with relapsed/refractory MCL.
February 19, 2024
Article
Jobelle Baldonado, MD, highlights the emergence of targeted therapies and the need for reflex-ordered molecular testing in early-stage lung cancer.
February 16, 2024
Video
Rachid Baz, MD, discusses findings from an analysis of cytopenias and infections in patients with multiple myeloma enrolled in the KarMMa-3 trial.